This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Kathrin Zuberbühler, PhD
Associate Director Antibody Engineering, Large Molecule Discovery at Charles River Laboratories at Antibody Engineering


Kathrin Zuberbühler received her PhD in applied biosciences from the Swiss Federal Institute of Technology (ETH Zurich). Her work in the group of Dario Neri focused on the development of vascular-targeting antibody drug conjugates and the application of phage display technology to isolate and optimize antibodies for the treatment of cancer and chronic inflammatory conditions. Kathrin then moved to Philochem AG, a spin-off company of ETH Zurich, where she worked on an antibody discovery program for molecular biomarkers. Awarded a postdoctoral fellowship from the Swiss National Science Foundation, Kathrin joined the lab of Charles Craik at University of California San Francisco where her research focused on the generation of antibodies against complex membrane proteins.

In 2016, Kathrin joined Five Prime Therapeutics, Inc. where she established the phage display antibody discovery platform as part of the newly formed antibody engineering and technology group. Kathrin headed the company’s phage display antibody discovery efforts for therapeutic, campaigns and implemented new technologies and antibody engineering strategies including panning approaches for membrane protein targets and library generation from immunized transgenic animals.

Kathrin joined Distributed Bio, now part of the Charles River family, in July 2020 where she is leading a team of scientists focused on antibody isolation and optimization.

Agenda Sessions

  • Discovery and Characterization of Nanobodies Directed Against SARS-COV2 Nucleocapsid For Use in Diagnostic Assays